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Meta-analysisChemotherapy-induced peripheral neuropathy (CIPN) is a disabling pain condition resulting from chemo-
therapy for cancer. Severe acute CIPN may require chemotherapy dose reduction or cessation. There is no
effective CIPN prevention strategy; treatment of established chronic CIPN is limited, and the prevalence
of CIPN is not known. Here we used a systematic review to identify studies reporting the prevalence of
CIPN. We searched Embase, Medline, CAB Abstracts, CINAHL, PubMed central, Cochrane Library, and
Web of Knowledge for relevant references and used random-effects meta-regression to estimate overall
prevalence. We assessed study quality using the CONSORT and STROBE guidelines, and we report ﬁndings
according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidance.
We provide a qualitative summary of factors reported to alter the risk of CIPN. We included 31 studies
with data from 4179 patients in our analysis. CIPN prevalence was 68.1% (57.7–78.4) when measured
in the ﬁrst month after chemotherapy, 60.0% (36.4–81.6) at 3 months and 30.0% (6.4–53.5) at 6 months
or more. Different chemotherapy drugs were associated with differences in CIPN prevalence, and there
was some evidence of publication bias. Genetic risk factors were reported in 4 studies. Clinical risk
factors, identiﬁed in 4 of 31 studies, included neuropathy at baseline, smoking, abnormal creatinine
clearance, and speciﬁc sensory changes during chemotherapy. Although CIPN prevalence decreases
with time, at 6 months 30% of patients continue to suffer from CIPN. Routine CIPN surveillance during
post-chemotherapy follow-up is needed. A number of genetic and clinical risk factors were identiﬁed that
require further study.
 2014 The Authors. Published by Elsevier B.V. on behalf of International Association for the Study of
Pain. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/3.0/).1. Introduction
Chemotherapy-induced peripheral neuropathy (CIPN) is a dis-
abling side effect of several commonly used antineoplastic agents.
The development of CIPN may require chemotherapy dose reduc-
tion or cessation, which can increase cancer-related morbidity
and mortality [17,31]. CIPN is a predominantly sensory neuropathy
that may be accompanied by motor and autonomic changes [62].
Similar to other neuropathic pain conditions, pain in CIPN can be
stimulus dependent or independent [66]. The pathophysiology ofCIPN is poorly understood, and treatments to prevent CIPN are
inadequate. Meta-analyses of clinical trials for CIPN prevention
report inconclusive results [1,49]. Treatment options for estab-
lished CIPN are also limited. Clinical trials of antiepileptic or anti-
depressant agents to treat other neuropathic pain conditions
have generally been negative [30,41,54,55]. Only 1 recent, dou-
ble-blind, randomized controlled trial showed improvement in
CIPN symptoms after 5 weeks of treatment with duloxetine [57].
Understanding of the epidemiology of CIPN is also limited [37].
Previous studies have largely focussed on individual chemothera-
peutic agents, with reported CIPN incidence rates ranging from
19% to more than 85% [23]. Annually 165,544 patients survive can-
cer in the United Kingdom, and more than 1 million in the United
States [12,44]. It is therefore important to provide a more precise
measure of the prevalence of CIPN to allow appropriate resource
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about treatment. Understanding risk factors (including genetic risk
factors) for CIPN may guide future research and treatment.
Previous reviews of CIPN have combined narrative review with
expert opinion, with potential risk of bias [15,28,29]. Here we pres-
ent what we believe to be the ﬁrst systematic review and meta-
analysis of the incidence and prevalence of CIPN. We also aimed
to assess the inﬂuence of potential publication bias on our estima-
tion of CIPN measures, and to seek empirical evidence of the
impact of study design factors.
2. Methods
2.1. Search strategy
We searched Embase, Medline, CAB Abstracts, CINAHL,
PubMed central, Cochrane Library and Web of Knowledge in July
2013 for English-language references. Searches were not limited
by date restrictions. Search terms were free text and included;
[‘‘Chemotherapy Induced Peripheral Neuropathy’’ OR ‘‘Chemo-
therapy Induced Neurotoxicity’’ OR ‘‘Chemotherapy Induced
Neurotoxicity Syndromes’’ OR ‘‘CIPN’’ OR ‘‘Oxaliplatin Induced
Peripheral Neuropathy’’ OR ‘‘Bortezomib Induced Peripheral Neu-
ropathy’’ OR ‘‘Paclitaxel Induced Peripheral Neuropathy’’ OR ‘‘Tax-
ane Induced Peripheral Neuropathy’’ OR ‘‘Cisplatin Induced
Peripheral Neuropathy’’ OR ‘‘Vincristine Induced Peripheral Neu-
ropathy’’ OR ‘‘Thalidomide Induced Peripheral Neuropathy’’ OR
‘‘Platinum Induced Peripheral Neuropathy’’ OR ‘‘Carboplatin
Induced Peripheral Neuropathy’’ OR ‘‘Docetaxel Induced Periphe-
ral Neuropathy’’ OR ‘‘Proteasome Inhibitor Induced Peripheral
Neuropathy’’ OR Neurotoxic Chemotherapy Induced Peripheral
Neuropathy’’ OR ‘‘Cancer Neuropathic Pain’’ OR ‘‘Chemotherapy
Induced Neuropathic Pain’’] [Search 1] AND [‘‘Prevalence’’ OR
‘‘Epidemiology’’ OR ‘‘Occurrence’’ OR ‘‘Burden’’] [Search 2] AND
[‘‘Predictors’’ OR ‘‘Risk Factors’’] [Search 3]. The search strategy
was adapted for each database (see supplementary text A). We
also hand searched reference lists of relevant studies and system-
atic reviews of CIPN prevention trials, and searched the databases
of National Institute for Health and Care Excellence (NICE) and
the Scottish Intercollegiate Guidelines Network (SIGN). Our
review followed an a priori protocol according to the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) guidelines [43]. The review protocol was registered on
the PROSPERO website before data extraction (registration no.
CRD42013005524) [11].
2.2. Inclusion and exclusion criteria and study selection
We included prospective observational studies of adult cancer
patients receiving chemotherapy of any type. Our deﬁnition of
observational studies included cohort studies in which patients
were prospectively identiﬁed and followed up using relevant pre-
deﬁned outcomes of interests. We also included control group data
from randomized controlled trials (RCTs) of CIPN prevention in
which details of the patients who developed CIPN were reported.
Studies were excluded if they described animal models of CIPN,
were investigating CIPN treatment or prevention, included pediat-
ric populations, or investigated other causes of neuropathy in
cancer patients (eg, pre-existing neuropathy such as diabetic
neuropathy or other cancer related causes of neuropathy such as
post-mastectomy).
Two investigators (M.S. and S.R.) independently read and
selected from all the retrieved references and abstracts. Discrepan-
cies between the reviewers’ selections were resolved by discussion.
Full texts of potentially eligible studies were retrieved (Fig. 1).2.3. Data extraction and quality assessment
We extracted data to a bespoke form, recording the prevalence
or incidence of CIPN, and any reported risk factors or predictors of
CIPN. We included all relevant outcomes determined after the end
of chemotherapy, noting the time (in relation to the end of chemo-
therapy) at which these were assessed. Where information was
incomplete we contacted authors by email. Two investigators
(M.S. and S.R.) extracted data, which were then entered into the
study database. Discrepancies were resolved by discussion and
agreement with a third reviewer (M.F.).
We assessed study quality according to the PRISMA guidelines
[43]. We evaluated risk of bias in individual studies using the fol-
lowing criteria: investigator blinding of any type, presence of a
control group, use of externally validated instruments for CIPN
assessment, clear description of statistical methods used to iden-
tify CIPN predictors, and description of longitudinal follow up.
Adherence of each study to relevant reporting criteria (STROBE or
CONSORT) was assessed [2,61]. We assessed the risk of bias for
our summary estimate by seeking evidence of publication bias,
selective outcome reporting bias (if a published protocol of the
included study was available), reporting of a sample size calcula-
tion, and whether the study reported participants lost to follow-up.
2.4. Data synthesis and analysis
Our primary outcome was the prevalence of CIPN. We used ran-
dom effects meta-regression to quantify heterogeneity and its
potential sources. We hypothesized that chemotherapy type and
the time of CIPN assessment would explain a large proportion of
the observed heterogeneity. Therefore, we included chemotherapy
type, last time point of CIPN assessment, and measures of study
quality as independent variables in our regression model. We also
planned for assessment of risk factors for CIPN across studies. We
assessed publication bias using funnel plots, Egger’s test, and trim
and ﬁll [22]. We appraised studies using STROBE criteria for obser-
vational studies and CONSORT criteria for trials. Where a criterion
was partially met, we considered, for the purposes of this analysis,
that it was completely met, for ease of calculation. In open label
studies (Table 1), we modiﬁed the CONSORT criteria by not consid-
ering the point for blinding, to account for the design of these stud-
ies. STATA 13.1 was used for statistical analyses.
3. Results
3.1. Studies included
We identiﬁed 4128 potentially relevant studies, and examined
the full text of 138. A total of 31 studies (involving 4179 patients)
[4–9,13,14,18,21,24–27,32–36,38,39,45–48,52,53,60,63–65] met
our inclusion criteria. A total of 30 studies reported the incidence
of CIPN (new CIPN cases divided by the population at risk). One
study reported CIPN prevalence (all CIPN cases divided by popula-
tion at risk) [26]. Because CIPN might have occurred, and resolved,
between study assessments, we calculated the prevalence of CIPN
at the time of each assessment [59].
3.2. Study characteristics
Of the 31 studies included, 15 were prospective cohort studies,
10 were RCTs, 5 were nonrandomized controlled trials, and 1 was a
cross-sectional cohort study. All nonrandomized controlled trials
were open labeled and not blinded. Eight of 10 RCTs (80%) reported
investigator blinding of some type. Blinded assessment of outcome
was reported in 3 of 14 prospective cohort studies. One prospective
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Fig. 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2009 ﬂow diagram.
M. Seretny et al. / PAIN

155 (2014) 2461–2470 2463cohort study also sought to validate genetic risk factor results in a
control group. Nine of 10 RCTs (90%) described a sample size calcu-
lation. Of all included studies, 22 (71%) reported study participant
dropout, giving reasons. In all, 14 of 31 study authors (45%) dis-
closed funders and/or whether they had a conﬂict of interest.
Adherence of studies to reporting guidelines is summarized in
Table 1. Of 31 studies, 26 (83.9%) used an assessment tool validated
for CIPN. All studies reporting CIPN risk factors described methods
used to identify these predictors.
3.3. CIPN incidence and prevalence
Of 4179 patients, 1960 developed CIPN (aggregate prevalence
48%). CIPN prevalence was 68.1% (95% CI = 57.7–78.4) within the
ﬁrst month of the end of chemotherapy, 60.0% (36.4–81.6) at
3 months, and 30.0% (6.4–53.5) at 6 months or later (Table 2).
There was considerable heterogeneity in the estimates from differ-
ent studies (I2 = 98.2, P < .001). The time of assessment accounted
for 36% of the observed heterogeneity (adjusted R2 = 0.365,
P < .001). An overview of the individual incidence reported in
included studies is shown in Table 1. We did not include thecumulative dose (CD) of chemotherapy (actual dose received) in
our meta-regression because standard and maximally tolerated
doses would differ substantially from drug to drug (study-speciﬁc
CD shown in Table 1). As expected, there was co-linearity between
the cancer type and the chemotherapy used; because we reasoned
that it is more likely that CIPN prevalence would be related to drug
than to cancer type, we considered only chemotherapy type in our
regression model (Table 3). The type of chemotherapy used
accounted for 32% of the observed heterogeneity in our sample
(adjusted R2 = 0.315, P < .04).
Methods used to assess the presence or grade of CIPN were too
diverse to include in the meta-regression. Of the 31 included stud-
ies, 8 deﬁned CIPN according to the National Cancer Institute Com-
mon Toxicity Criteria (NCI-CTC), 1 study used the European
Organisation for Research and Treatment of Cancer (EORTC) Qual-
ity of Life Questionnaire 30 (QLQ – 30) combined with neurological
examination, 1 used in-depth neurophysiological examination
(NPS), 1 used a standard neurological examination, and 1 used
the Total Neuropathy Score (TNSc). The remaining 18 studies used
a combination of 2 or more of the above, and 1 study used skin
biopsy (Table 3). To investigate any impact of neurophysiological
Table 1
Overview of included studies.
First author (year) Study type and quality
(CONSORT/STROBE score)
Incidence (95% CI) Main cancer class
(chemotherapy)
Dose (mg/m2)
(mean or cumulative)
Antonacopoulou (2009)* Prospective cohort 58.8% (42.2–75.3) Colorectal (oxaliplatin) —
Argyriou (2006) Prospective cohort (18/22) 61.5% (35.1–87.9) Breast (paclitaxel) 1980
42.8% (16.9–68.7) Lung (cisplatin) 720
Argyriou (2007) [8] Prospective cohort (19/22) 64% (45.2–82.8) Colorectal (oxaliplatin) 1740
Argyriou (2007) Prospective cohort (19/22) 69.2% (44.1–94.3) Multiple solid (cisplatin and paclitaxel) 1267
Argyriou (2012) Prospective cohort (19/22) 83.3% (77.3–89.3) Colorectal (oxaliplatin) 1646
Argyriou (2013) Prospective cohort (20/22) 84.5% (79.4–89.5) Colorectal (oxaliplatin) 1651
Attal (2009) Prospective cohort (19/22) 66.6% (44.8–88.4) Colorectal (oxaliplatin) 1278
Baldwin (2012) Prospective cohort (20/22) 67.2% (64.1–70.3) Breast (paclitaxel) —
Cascinu (1995) RCT (18/25) 64% (45.2–82.8) Gastrointestinal (cisplatin) —
Cascinu (2002) RCT (16/25) 78.9% (60.6–97.3) Colorectal (oxaliplatin) 783
Chaudhary (2008)

Prospective cohort (13/22) 96.2% (89.2–103) Multiple myeloma (bortezomib and thalidomide) 36
Dimopoulos (2011) RCT (21/25) 46.7% (41.4–52.1) Multiple myeloma (bortezomib) 384
Gandara (1995)

RCT (18/25) 12.1% (5.6–185) Ovarian and lung (cisplatin) 379
Ghoreishi (2012) RCT (19/25) 59.2% (40.7–77.8) Breast (paclitaxel) —
Glendenning (2010)

Cross sectional cohort (21/22) 20.1% (15.5–24.7) Testicular (cisplatin and vincristine) 400
Gobran (2013) RCT (13/25) 70% (53.6–86.4) Colorectal (oxaliplatin) 763
Ishibashi (2010) RCT (20/25) 93.7% (81.9–105) Colorectal (oxaliplatin) 728
Johnson (2011) RCT (23/25) 32.1% (29.1–34.9) Multiple myeloma (thalidomide) —
19.6% (16.3–22.9) (Vincristine) —
Kawakami (2012)

Prospective cohort (14/22) 76% (64.1–87.8) Lung (cisplatin and paclitaxel) —
Kemp (1996) RCT (19/25) 675% (59.2–75.8) Gynecological (cisplatin) —
Krishnan (2005) Prospective cohort (16/22) 50% (25.5–74.5) Colorectal (oxaliplatin) 1200
Lin (2006) Randomised trial (15/24) 90% (71.4–108) Colorectal (oxaliplatin) 1200
Milla (2009) Randomised trial (11/24) 92.8% (79.3–106) Colorectal (oxaliplatin) 772
Pace (2003) Randomised trial (11/24) 85.7% (67.4–104) Multiple solid (cisplatin) 420
Pace (2007) Prospective cohort (14/22) 92.8% (79.4–106) Breast (paclitaxel) 1744
Pace (2010) RCT (19/25) 41.6% (21.9–61.4) Multiple solid (cisplatin) 450
Planting (1999) Randomised trial (13/24) 13.5% (2.5–24.5) Multiple solid (cisplatin) 401
Plasmati (2002) Prospective cohort (15/22) 96% (88.3–103) Multiple myeloma (thalidomide) 18
Van der Hoop (1999) RCT (12/25) 41.6% (13.7–69.5) Gynecological (cisplatin) 416
Von Schlippe (2001) Prospective cohort (9/22) 17.2% (3.4–30.9) Testicular (cisplatin) —
Won (2012) Prospective cohort (16/22) 40.6% (30.8–50.4) Colorectal (oxaliplatin) 935
Abbreviation: RCT, randomized controlled trial (note that randomised trials, as opposed to RCTs, did not have blinding or placebo).
— Cumulative or average dose not reported. Reported cumulative dose refers to actual dose received.
* Abstract only available; STROBE assessment not possible. Where upper 95% conﬁdence intervals exceeded 100, only 100% were recorded, as this is clinically interpretable.

Study pooled incidence across chemotherapy types included.

Study pooled incidence across cancer types.
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post hoc sensitivity analysis. In all, 17 studies (449 patients) used
NPS to assess for CIPN; 16 of these used NPS in combination with
another assessment method. In these 17 studies, CIPN prevalence
was higher; 73.3% (58.6–87.3) within 1 month of chemotherapy
cessation, 70.1% (41.8–98.4) at 3 months, and 39.9% (3.9–76.0) at
6 months or more.
For publication bias, although Egger’s test did not suggest asym-
metry in the funnel plot at a conﬁdence level of P = .05 (95% CI of
intercept 0.64 to 7.8); trim and ﬁll analysis did impute 14
theoretical missing studies. These 2 approaches to assess for
publication bias are known to have different sensitivities [58].
3.4. CIPN risk factors
Eight of the included studies assessed risk factors for CIPN
(Table 4) [8,9,21,26,33,34,48,65]. Four genome-wide association
studies (GWAS), totaling 2671 patients, sought single nucleotide
polymorphisms (SNPs) associated with CIPN [9,33,48,65]. All
GWAS used validation datasets and conducted genotyping blinded
to clinical status. These reported polymorphisms associated with a
range of proteins, including voltage-gated sodium channels, Schw-
ann cell function–related proteins, receptors for cell surface colla-
gen, receptors involved in neuronal apoptosis, neuronal crest cell
development, and an enzyme involved in pyruvate metabolism.
Four studies (701 patients) used statistical modeling to report
clinical risk factors for CIPN [8,21,26,34]. Two of these studies
included 50 patients or fewer. No study used a separate data setto validate candidate risk factors. Reported clinical risk factors
for CIPN included baseline neuropathy, a history of smoking,
decreased creatinine clearance, and speciﬁc sensory changes dur-
ing chemotherapy treatment, including cold allodynia (pain in
response to a nonpainful cold stimulus) and cold hyperalgesia
(exaggerated pain in response to a painful cold stimulus, 20 C).
4. Discussion
4.1. CIPN prevalence
This systematic review and meta-regression suggests a high
overall prevalence of CIPN, maximum within the ﬁrst month after
treatment, and falling over time. Approximately one-third of
patients can expect to have chronic CIPN 6 months or more after
the end of chemotherapy; this has a signiﬁcant negative impact
on long-term quality of life for which effective treatment is needed.
The lack of uniformity in CIPN assessment methods make
between-study comparisons difﬁcult. Authors used 5 assessment
methods (NCI-CTC, TNSc, EORTC QLQ-C30, neuro-physiological
examination, which included nerve conduction studies and/or
quantitative sensory testing, and neurological examination) alone
or in combination. Of these, only the EORTC QLQ-C30 and quanti-
tative sensory testing component of neurophysiological examina-
tion explicitly assess pain as a symptom of CIPN. It is known that
although CIPN most frequently presents with pain, motor and
other sensory symptoms may also be present [40]. Use of combina-
tions of CIPN and pain assessment tools has been suggested as a
Table 2
Comparison of prevalence related to time of CIPN assessment.
Time of assessment
(after cessation of chemotherapy)
Prevalence (95% CI) Studies included Total no. of patients in group
61 mo 68.1% (57.7–78.4) Antonacopolou 2009 2085
Argyriou 2007
Argyriou 2012
Argyriou 2013
Baldwin 2012
Cascinu 1995
Cascinu 2002
Chaudhry 2008
Dimopoulos 2011*
Gandara 1995
Ghoreishi 2012
Gobran 2013*
Ishibashi 2010
Kawakami 2012
Krishnan 2005*
Lin 2006
Milla 2009*
Pace 2003
Pace 2007*
Pace 2010
Van Der Hoop 1999
Won 2012
3 mo 60.0% (36.4–81.6)

Argyriou 2006 234
Argyriou 2007
Kemp 1996
Planting 1999
Plasmati 2007
P6 mo 30.0% (6.4–53.5)

Johnson 2011

1860
Attal 2009
Glendenning 2010
Von Schlippe 2001
Abbreviations: CI, conﬁdence interval; CIPN, chemotherapy-induced peripheral neuropathy.
* Studies included longer-term CIPN follow up but did not provide enough details at these later time points to allow use of data in the meta-
regression.

Wide conﬁdence interval likely due to small number of studies assessing CIPN beyond this time point.

Study considered CIPN only after induction therapy and not during maintenance.
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[67]. There have been recent attempts to standardize CIPN assess-
ment and reporting, and we encourage investigators to consider
these when developing study protocols [15,16].
Three of the 5 largest studies in our sample did not include the
mildest grades of CIPN [9,24,45]. The prevalence of CIPN is there-
fore likely to be higher than reported here. Early detection of mild
CIPN might become important if effective prevention or manage-
ment strategies become available. A lower incidence in these larger
studies is an alternative explanation for the funnel plot asymmetry
detected by trim and ﬁll analysis [58].
Current clinical guidelines support use of NPS methods in the
diagnosis of suspected CIPN [19,56]. Studies using this approach
reported a higher prevalence of CIPN, but whether this is a clini-
cally signiﬁcant problem is not clear.
We found signiﬁcant heterogeneity between studies. In meta-
analyses aimed at providing a best estimate of, for instance, drug
efﬁcacy, signiﬁcant heterogeneity usually limits the usefulness of
pooled data. In contrast, because the etiology and epidemiology
of CIPN are so poorly understood, we believe that investigating
the sources of heterogeneity is important. Speciﬁcally, it might
provide insight into the impact of length of assessment and chemo-
therapy type on the incidence and prevalence of CIPN. Further-
more, as expected, a substantial proportion of the heterogeneity
that we observed was accounted for by chemotherapy type, which
was related to the cancer type. Although the primary interest of
many clinicians will be the prevalence of CIPN for speciﬁc chemo-
therapeutics, CIPN treatment decisions are routinely based on data
from treatment trials that have recruited patients irrespective of
the chemotherapy that they were prescribed [57].4.2. Risk factors for CIPN
Four studies used multivariate statistical modeling to identify
clinical risk factors for CIPN [8,21,26,34]. Despite using valid statis-
tical approaches, these studies did not verify identiﬁed risk factors
in new population datasets. Consequently, their results are proba-
bly affected by the statistical biases underpinning these types of
predictive calculations [3,42]. To our knowledge, these are the only
studies that describe baseline neuropathy, smoking, and decreased
creatinine clearance as risk factors for CIPN. In contrast, description
of sensory changes during chemotherapy treatment, including
increased pain and nerve hyperexcitability, have previously been
documented as predictors of CIPN [20,42]. The postulated mecha-
nisms underpinning these sensory phenomena include axonal
hyperexcitability and nociceptor sensitization. These processes
may be important in CIPN development, and, to some degree, they
ﬁt with the mechanisms described in other neuropathic conditions
related to systemic diseases, including human immunodeﬁciency
virus (HIV) and multiple sclerosis [42,64]. There is ongoing debate
about the relative importance of etiology in determining the
underlying mechanisms of neuropathic pain [19,56,62].
Four studies reported genetic risk factors for CIPN. The functions
of the identiﬁed genes ﬁt with the postulated pathophysiological
mechanisms underpinning CIPN [50]. The recent comprehensive
review by Cavaletti et al. discusses these mechanisms in detail.
All 4 included studies were, to some degree, affected by the univer-
sal limitations inﬂuencing pharmacogenetic studies: inadequate
sample size, CIPN assessment tools, and use and size of a replication
cohort. Despite these possible limitations, the potential clinical use-
fulness of pharmacogenetic studies in CIPN has recently been
Table 3
Studies stratiﬁed by drug type.
Study type
(CONSORT/STROBE)
Main cancer
class
CIPN severity report
(count by grade if given)
CIPN assessment time points CIPN assessment
method(s)
Oxaliplatin: 72.3% (95% CI = 59.7–86.8)
Antonacopoulou
(2009)*
Prospective cohort Colorectal NR Unclear TNSc
Argyriou (2007) [8] Prospective cohort Colorectal Grade I (6/16) Baseline TNSc
Grade II (8/16) Cycles 4, 8, 12 NPS
Grade III (2/16) NCI-CTC
Argyriou (2012) Prospective cohort Colorectal Grade I (38/125) Baseline TNSc
Grade II (46/125) Cycles 3, 6 (FOLFOX) NPS
Grade III (41/125) Cycles 4, 8 (XELOX) NCI-CTC
Argyriou (2013)

Prospective cohort Colorectal Grade I (62/169) Baseline TNSc
Grade II (46/169) Cycle 6, 12 (FOLFOX) NCI-CTC
Grade III (61/169) Cycles 4, 8 (XELOX)
Attal (2009) Prospective cohort Colorectal Sensory symptom counts
described as means/
individual
Baseline NCI-CTC
Cycle 3, 6, 9 NPS
12 ± 2 mo after chemo end (EORTC) QLQ-C30
Cascinu (2002) RCT Colorectal Grade I (4/15) Baseline NCI-CTC
Grade II (6/15) Cycles 4, 8, 12 NPS
Grade III (4/15) Within 2 wk of chemo end
Grade IV (1/15)
Gobran (2013) RCT Colorectal Grade I (7/21) Unclear if at baseline NCI-CTC
Grade II (0/21) At each chemo cycle until end of chemo
(variable no. of cycles)
Grade III (14/21) Longer follow-up for those with CIPN (but
denominator unclear)
Grade IV (0/21)
Ishibashi (2010) RCT Colorectal Grade I (15/15) Baseline NCI-CTC
Grade II (1/15) At each chemo cycle until end of chemo
Grade III (0/15)
Grade IV (0/15)
Krishnan (2005) Prospective cohort Colorectal NR No baseline NCI-CTC
Within 1 mo of chemo end only reported
assessment
NPS
TNSc
Lin (2006) Controlled trial Colorectal Grade I (1/9) Baseline NCI-CTC
Grade II (5/9) Cycles 4, 8, 12 NPS
Grade III (3/9) Within 2 wk of end of chemo
Grade IV (0/9)
Milla (2009) Controlled trial Colorectal Grade I (0/13) Baseline NCI-CTC
Grade II (9/13) Cycles 5, 9, 12 NES
Grade III (4/13) (Some followed up longer but denominator
unclear)
Won (2012) Prospective cohort Colorectal NR Unclear if at baseline NCI-CTC
At each chemo cycle until end of chemo
(variable no. of cycles)
NES
Cisplatin: 42.2% (95% CI = 21.3–63.1)
Argyriou (2006)

Prospective cohort Lung Reported by age group
only
Baseline PNS
Cycles 3, 6 NPS
3 mo after chemo end
Cascinu (1995) RCT Gastrointestinal Grade I (3/16) Baseline NCI-CTC
Grade II (10/16) After 9 and 15 wk of therapy NPS
Grade III (2/16) Within 1 wk after end of chemo
Grade IV (1/16)
Gandara (1995) RCT Ovarian and
lung
Only grade P3 reported Unclear if at baseline NCI-CTC
At each cycle until chemo end (variable no. of
cycles)
Study stopped early after interim analysis due
to high toxicity in intervention group
Kemp (1996) RCT Gynecological Grade I (31/81) Baseline NCI-CTC
Grade II (35/81) Cycles 4, 5, 6 NES
Grade III (15/81) Monthly after chemo for 3 mo
Pace (2003) Controlled trial Multiple solid Grade I (6/12) Baseline TNSc
Grade II (4/12) After 6 cycles NES
Grade III & IV (2/12)
Pace (2010) RCT Multiple solid Only grade P3 reported Baseline TNSc
Every cycle for 3 cycles NPS
1 mo after chemo end
Planting (1999) Controlled trial Multiple solid Grade I (5/5) Baseline NCI-CTC
Cycle 3, 6 NES
3 mo after chemo end
(Longer follow-up but no denominator info)
Van der Hoop (1999) Controlled trial Gynecological Mean vibration threshold Baseline NES
Cycles 2, 4, 6
End of chemo
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Table 3 (continued)
Study type
(CONSORT/STROBE)
Main cancer
class
CIPN severity report
(count by grade if given)
CIPN assessment time points CIPN assessment
method(s)
Von Schlippe (2001) Prospective cohort Testicular Grade I (4/5) Unclear if at baseline NPS
Grade II (1/5) Every 6 wk for ﬁrst 6 mo after chemotherapy
Thereafter every 2 mo for median of 4 y (range
2–8 y)
Cisplatin or carboplatin and paclitaxel: 73% (95% CI = 36.2–109.7)
Argyriou (2007) Prospective cohort Multiple solid Mild (2/9) Baseline PNS
Moderate (6/9) Cycle 3, 6 NPS
Severe (1/9) 3 mo after chemo end
Kawakami (2012)§ Prospective cohort Lung % Severity with
cumulative dose
Baseline NCI-CTC
Daily during cycle 1
Cycle 2, 3, 4
Chemo end
Cisplatin and vincristine: 20.1% (95% CI = 26.2 to 66.5)
Glendenning (2010)§ Cross-sectional
cohort
Testicular Only grade P3 reported Recruited patients at least 5 y post-treatment (EORTC) QLQ-C30
Assessed once for this prevalence study NES
Paclitaxel: 70.8% (95% CI = 43.5–98.1)
Argyriou (2006)

Prospective cohort Breast Reported by age group
only
Baseline PNS
Cycles 3, 6 NPS
3 mo after chemo end
Baldwin (2012) Prospective cohort Breast Only grade P2 reported Unclear if at baseline NCI-CTC
Cycles 4, 6
Within 1 mo of chemo end
Ghoreishi (2012) RCT Breast Mild (10/16) Baseline TNSc
Moderate (5/16) 1 mo after chemo end NPS
Severe (1/16)
Pace (2007) Prospective cohort Breast Mean neurotoxicity scores
reported
Baseline TNSc
After 12 wk of chemo NPS
After 24 wk of chemo
Vincristine: 19.6% (95% CI 26.6 to 65.9)
Johnson (2011)

RCT Multiple
myeloma
GradeP I 31.8% Unclear if at baseline NCI-CTC
GradeP II 11% At each cycle
GradeP III 3.6% For 6 months after chemo end for induction (ie,
36 wk from start of induction therapy)
Thalidomide: 63.5% (95% CI = 29.3–97.8)
Johnson (2011)

RCT Multiple
myeloma
Grade details not reported Unclear if at baseline NCI-CTC
At each cycle
For 6 mo after end of chemo for induction (ie,
36 weeks from start of induction therapy)
Plasmati (2002) Prospective cohort Multiple
myeloma
Grade I (12/24) Baseline NCI-CTC
Grade II (6/24) After 4 mo of chemo NPS
Subclincial (6/24) 3 mo after stem cell transplantation
Bortezomib: 46.7% (95% CI = 0.3–93.1)
Dimopoulos (2011) RCT Multiple
myeloma
Grade I NR Unclear if at baseline NCI-CTC
Grade II (64/159) Every 3 wk until
Grade III (45/159) 1 mo after last chemo dose
Grade IV (1/159) Longer follow-up but no denominator data
Bortezomib and thalidomide: 96.2% (95% CI = 49.7–143)
Chaudhary (2008) Prospective cohort Multiple
myeloma
Grade P2 reported Baseline TNSc
Cycles 2, 4, 6, 8 NPS
End of chemo Skin biopsy
Note skin biopsy at baseline and end of chemo
only
Abbreviations: Chemo, chemotherapy; CIPN, chemotherapy-induced peripheral neuropathy; EORTC, European Organization for Research and Treatment of Cancer; CI,
conﬁdence interval; NCT-CTC, National Cancer Institute Common Toxicity Criteria; NES, neurological examination; NPS, neurophysiological examination (quantitative
sensory testing and/or nerve conduction studies); NR, not reported; PNS, Modiﬁed peripheral neuropathy score; RCT, randomized controlled trial; TNSc, total neuropathy
score.
* Abstract only available.

Authors report both acute and chronic CIPN grade counts, only acute given here.

Raw data obtained from author or reported in paper, allowing counts reported in single study to be split by chemotherapy type.
§ Studies pooled CIPN counts across chemotherapy types included.
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studies to standardized study design and methods will likely aid
the advance of personalized oncology, possibly having an impact
on CIPN prevalence in the future.
4.3. Limitations of this review
It is possible that we have omitted relevant studies despite
our detailed search strategy, and we speciﬁcally excludednon–English language studies. Multivariate meta-regression would
have allowed us to investigate interactions between various
factors, but there are too few studies for this approach to be
reliable. Because we expected there to be a broad range of CIPN
assessment methods used, we did not plan to explore their
impact. Our analysis of the impact of NPS as a component of
the assessment of CIPN is post hoc and therefore should be
interpreted with caution. We did not speciﬁcally seek out
assessments for pain in CIPN in included studies and therefore
Table 4
CIPN risk factors.
Study Category of risk factor reported Data source of study Sample size of study (N) Risk factor details
Argyriou (2013) Genetic Prospective cohort 200 SNC4A-rs2302237 OR = 2.65 (1.15–6)
SCN10A-rs1263292 OR = 0.39 (0.17–0.88)
Attal (2009) Clinical Prospective cohort 18 Cold allodynia OR = 39 (1.8–817)
Cold hyperalgesia OR = 3.9 (1.0–1.20)
Baldwin (2012) Genetic Prospective cohort 855 FGD4-rs10771973 HR = 1.57 (1.30–1.91)
Dimopoulos (2011) Clinical RCT 340 Baseline neuropathy HR = 1.79 (p < 0.01)
Glendenning (2010) Clinical and treatment-related Cross-sectional cohort 293 Cisplatin dose increase OR = 1.91 (1.61–2.26)
Carboplatin dose increase OR = 1.26 (1.04–1.52)
Age at follow-up OR = 1.06 (1.04–1.08)
Johnson (2011)
⁄
Genetic RCT 970 + 550 ABCA1-rs363717 OR = 0.71 (0.52–0.98)
ICAM1-rs1799969 OR = 0.67 (0.44–1.03)
PPARD-rs2076169 OR = 0.60 (0.38–095)
SERPINB2-rs6103 OR = 0.70 (0.52–0.95)
SLC12A6-rs7164902 OR = 0.60 (0.44–0.80)
Kawakami (2012) Clinical Prospective cohort 50 Smoking history pack-years HR = 1.03 (1.0–1.05)
Decreased creatinine clearance HR = 0.96 (0.92–0.99)
Won (2012)

Genetic Prospective cohort 96 TAC1-rs10486003
FOXC1-rs2338
ITGA1-rs830884
ACYP2-rs843748
DLEU7-rs797519
Abbreviations: CIPN, chemotherapy-induced peripheral neuropathy; HR, hazard ratio (95% conﬁdence interval or signiﬁcance level); OR, odds ratio (95% conﬁdence interval);
RCT, randomized controlled trial; SNP, single nucleotide polymorphism.
Note that Jonson et al. reported ORs for both populations included in their analysis. Only 1 set of ORs is reported here. All effect sizes reported here are directly from the cited
studies.
* SNP association with CIPN grade P2 only.

Won et al. reported the overall predictive accuracy of the multiple logistic regression model yielding the 5 positive single nucleotide polymorphisms (SNPs), 72.8% (65.8–
79.9), as opposed to ORs for individual SNPs.
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out analysis.
4.4. Strengths of this review
Our meta-analysis quantiﬁes CIPN prevalence across most che-
motherapy and cancer types. This allows our prevalence measures
to be used by clinicians when deciding between chemotherapy
types and regimens. It is also useful for planning future CIPN treat-
ment studies. In addition, these ﬁndings may be useful for both
resource allocation and research planning. Our pooled prevalence
also allows direct estimation of economic costs of CIPN resulting
from the chemotherapeutics and cancer types included in our
review [51].
In this ﬁrst meta-analysis investigating epidemiological mea-
sures of CIPN, we highlight the effect of the time of assessment,
after chemotherapy cessation, on CIPN prevalence. This has impli-
cations for surveillance of CIPN at follow up, clinical care planning,
and patient expectations. Speciﬁcally, our results may contribute
to explaining the risks of developing CIPN, and its likely natural
history, to patients at consent for chemotherapy. In broad terms,
around two-thirds of patients will suffer from CIPN in the ﬁrst
month after chemotherapy, but in only one-half of these will CIPN
have resolved by six months. Finally, we have conﬁrmed the urgent
need for a standardized approach to the diagnosis of CIPN, reaf-
ﬁrming ongoing efforts such as those of the chemotherapy-induced
peripheral neuropathy outcome measures standardization study
(CI-PERINOMS) group [67].
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